1. Li, Z., Maglione, M., Tu, W., Mojica, W., Arterburn, D., Shugarman, L.R., Hilton, L., Suttorp, M., Solomon, V., Shekelle, P.G., and Morton, S.C.: Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 142:532-546, 2005
2. Kojima, M., Hosoda, H., and Kangawa, K.: Purification and distribution of ghrelin: the natural endogenous ligand for the growth hormone secretagogue receptor. Horm Res 56 Suppl 1:93-97, 2001
3. Kojima, M., Hosoda, H., Date, Y., Nakazato, M., Matsuo, H., and Kangawa, K.: Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402:656-660, 1999
4. Ariyasu, H., Takaya, K., Tagami, T., Ogawa, Y., Hosoda, K., Akamizu, T., Suda, M., Koh, T., Natsui, K., Toyooka, S., Shirakami, G., Usui, T., Shimatsu, A., Doi, K., Hosoda, H., Kojima, M., Kangawa, K., and Nakao, K.: Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J Clin Endocrinol Metab 86:4753-4758, 2001
5. Date, Y., Kojima, M., Hosoda, H., Sawaguchi, A., Mondal, M.S., Suganuma, T., Matsukura, S., Kangawa, K., and Nakazato, M.: Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 141:4255-4261, 2000
6. Date, Y., Nakazato, M., Hashiguchi, S., Dezaki, K., Mondal, M.S., Hosoda, H., Kojima, M., Kangawa, K., Arima, T., Matsuo, H., Yada, T., and Matsukura, S.: Ghrelin is present in pancreatic alpha-cells of humans and rats and stimulates insulin secretion. Diabetes 51:124-129, 2002
7. Dezaki, K., Hosoda, H., Kakei, M., Hashiguchi, S., Watanabe, M., Kangawa, K., and Yada, T.: Endogenous ghrelin in pancreatic islets restricts insulin release by attenuating Ca2+ signaling in beta-cells: implication in the glycemic control in rodents. Diabetes 53:3142-3151, 2004
8. Hosoda, H., Kojima, M., Matsuo, H., and Kangawa, K.: Ghrelin and des-acyl ghrelin: two major forms of rat ghrelin peptide in gastrointestinal tissue. Biochem Biophys Res Commun 279:909-913, 2000
9. Lee, H.M., Wang, G., Englander, E.W., Kojima, M., and Greeley, G.H., Jr.: Ghrelin, a new gastrointestinal endocrine peptide that stimulates insulin secretion: enteric distribution, ontogeny, influence of endocrine, and dietary manipulations. Endocrinology 143:185-190, 2002
10. Prado, C.L., Pugh-Bernard, A.E., Elghazi, L., Sosa-Pineda, B., and Sussel, L.: Ghrelin cells replace insulin-producing beta cells in two mouse models of pancreas development. Proc Natl Acad Sci U S A 101:2924-2929, 2004
11. Tschop, M., Smiley, D.L., and Heiman, M.L.: Ghrelin induces adiposity in rodents. Nature 407:908-913, 2000
12. Horvath, T.L., Diano, S., Sotonyi, P., Heiman, M., and Tschop, M.: Minireview: ghrelin and the regulation of energy balance--a hypothalamic perspective. Endocrinology 142:4163-4169, 2001
13. Cummings, D.E., and Foster, K.E.: Ghrelin-leptin tango in body-weight regulation. Gastroenterology 124:1532-1535, 2003
14. Cummings, D.E., Purnell, J.Q., Frayo, R.S., Schmidova, K., Wisse, B.E., and Weigle, D.S.: A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 50:1714-1719, 2001
15. Nagaya, N., Uematsu, M., Kojima, M., Date, Y., Nakazato, M., Okumura, H., Hosoda, H., Shimizu, W., Yamagishi, M., Oya, H., Koh, H., Yutani, C., and Kangawa, K.: Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic/catabolic factors. Circulation 104:2034-2038, 2001
16. Otto, B., Cuntz, U., Fruehauf, E., Wawarta, R., Folwaczny, C., Riepl, R.L., Heiman, M.L., Lehnert, P., Fichter, M., and Tschop, M.: Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa. Eur J Endocrinol 145:669-673, 2001
17. Tolle, V., Kadem, M., Bluet-Pajot, M.T., Frere, D., Foulon, C., Bossu, C., Dardennes, R., Mounier, C., Zizzari, P., Lang, F., Epelbaum, J., and Estour, B.: Balance in ghrelin and leptin plasma levels in anorexia nervosa patients and constitutionally thin women. J Clin Endocrinol Metab 88:109-116, 2003
18. Wisse, B.E., Frayo, R.S., Schwartz, M.W., and Cummings, D.E.: Reversal of cancer anorexia by blockade of central melanocortin receptors in rats. Endocrinology 142:3292-3301, 2001
19. Asakawa, A., Inui, A., Kaga, T., Yuzuriha, H., Nagata, T., Ueno, N., Makino, S., Fujimiya, M., Niijima, A., Fujino, M.A., and Kasuga, M.: Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin. Gastroenterology 120:337-345, 2001
20. Wren, A.M., Small, C.J., Abbott, C.R., Dhillo, W.S., Seal, L.J., Cohen, M.A., Batterham, R.L., Taheri, S., Stanley, S.A., Ghatei, M.A., and Bloom, S.R.: Ghrelin causes hyperphagia and obesity in rats. Diabetes 50:2540-2547, 2001
21. Shimbara, T., Mondal, M.S., Kawagoe, T., Toshinai, K., Koda, S., Yamaguchi, H., Date, Y., and Nakazato, M.: Central administration of ghrelin preferentially enhances fat ingestion. Neurosci Lett 369:75-79, 2004
22. Theander-Carrillo, C., Wiedmer, P., Cettour-Rose, P., Nogueiras, R., Perez-Tilve, D., Pfluger, P., Castaneda, T.R., Muzzin, P., Schurmann, A., Szanto, I., Tschop, M.H., and Rohner-Jeanrenaud, F.: Ghrelin action in the brain controls adipocyte metabolism. J Clin Invest 116:1983-1993, 2006
23. Abizaid, A., Liu, Z.W., Andrews, Z.B., Shanabrough, M., Borok, E., Elsworth, J.D., Roth, R.H., Sleeman, M.W., Picciotto, M.R., Tschop, M.H., Gao, X.B., and Horvath, T.L.: Ghrelin modulates the activity and synaptic input organization of midbrain dopamine neurons while promoting appetite. J Clin Invest, 2006
24. Jerlhag, E., Egecioglu, E., Dickson, S.L., Douhan, A., Svensson, L., and Engel, J.A.: Ghrelin administration into tegmental areas stimulates locomotor activity and increases extracellular concentration of dopamine in the nucleus accumbens. Addict Biol 12:6-16, 2007
25. Jerlhag, E., Egecioglu, E., Dickson, S.L., Andersson, M., Svensson, L., and Engel, J.A.: Ghrelin stimulates locomotor activity and accumbal dopamine-overflow via
1. central cholinergic systems in mice: implications for its involvement in brain reward. Addict Biol 11:45-54, 2006
26. Naleid, A.M., Grace, M.K., Cummings, D.E., and Levine, A.S.: Ghrelin induces feeding in the mesolimbic reward pathway between the ventral tegmental area and the nucleus accumbens. Peptides 26:2274-2279, 2005
27. Jewett, D.C., Lefever, T.W., Cameron, C.R., Flashinski, D.P., Koffarnus, M.N., Beaudry, A.R., Masters, K.M., Grace, M.K., and Levine, A.S. 2003. Ghrelin increases break point under a progressive ratio 1 reinforcement schedule in rats. New Orleans, LA.
28. Azzara, A.V., Schuss, B., Hong, S., and Schwartz, G.J. 2005. Peripheral ghrelin administration increases food intake, meal size, and progressive ratio responding for food. In Society for the Study of Ingestive Behavior: Annual Meeting C. Zuberbuehler, editor. Sheraton Station Square Hotel, Pittsburgh, PA, USA.
29. Ariyasu, H., Takaya, K., Hosoda, H., Iwakura, H., Ebihara, K., Mori, K., Ogawa, Y., Hosoda, K., Akamizu, T., Kojima, M., Kangawa, K., and Nakao, K.: Delayed short-term secretory regulation of ghrelin in obese animals: evidenced by a specific RIA for the active form of ghrelin. Endocrinology 143:3341-3350, 2002
30. Tschop, M., Weyer, C., Tataranni, P.A., Devanarayan, V., Ravussin, E., and Heiman, M.L.: Circulating ghrelin levels are decreased in human obesity. Diabetes 50:707-709, 2001
31. Cummings, D.E., Weigle, D.S., Frayo, R.S., Breen, P.A., Ma, M.K., Dellinger, E.P., and Purnell, J.Q.: Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 346:1623-1630, 2002
32. Goldstone, A.P.: Prader-Willi syndrome: advances in genetics, pathophysiology and treatment. Trends Endocrinol Metab 15:12-20, 2004
33. Holm, V.A., Cassidy, S.B., Butler, M.G., Hanchett, J.M., Greenswag, L.R., Whitman, B.Y., and Greenberg, F.: Prader-Willi syndrome: consensus diagnostic criteria. Pediatrics 91:398-402, 1993
34. Cummings, D.E., Clement, K., Purnell, J.Q., Vaisse, C., Foster, K.E., Frayo, R.S., Schwartz, M.W., Basdevant, A., and Weigle, D.S.: Elevated plasma ghrelin levels in Prader Willi syndrome. Nat Med 8:643-644, 2002
35. Goldstone, A.P., Patterson, M., Kalingag, N., Ghatei, M.A., Brynes, A.E., Bloom, S.R., Grossman, A.B., and Korbonits, M.: Fasting and postprandial hyperghrelinemia in Prader-Willi syndrome is partially explained by hypoinsulinemia, and is not due to peptide YY3-36 deficiency or seen in hypothalamic obesity due to craniopharyngioma. J Clin Endocrinol Metab 90:2681-2690, 2005
36. Haqq, A.M., Farooqi, I.S., O'Rahilly, S., Stadler, D.D., Rosenfeld, R.G., Pratt, K.L., LaFranchi, S.H., and Purnell, J.Q.: Serum ghrelin levels are inversely correlated with body mass index, age, and insulin concentrations in normal children and are markedly increased in Prader-Willi syndrome. J Clin Endocrinol Metab 88:174-178, 2003
37. Paik, K.H., Jin, D.K., Song, S.Y., Lee, J.E., Ko, S.H., Song, S.M., Kim, J.S., Oh, Y.J., Kim, S.W., Lee, S.H., Kim, S.H., Kwon, E.K., and Choe, Y.H.: Correlation between fasting plasma ghrelin levels and age, body mass index (BMI), BMI
2. percentiles, and 24-hour plasma ghrelin profiles in Prader-Willi syndrome. J Clin Endocrinol Metab 89:3885-3889, 2004
38. Tauber, M., Conte Auriol, F., Moulin, P., Molinas, C., Delagnes, V., and Salles, J.P.: Hyperghrelinemia is a common feature of Prader-Willi syndrome and pituitary stalk interruption: a pathophysiological hypothesis. Horm Res 62:49-54, 2004
39. Choe, Y.H., Song, S.Y., Paik, K.H., Oh, Y.J., Chu, S.H., Yeo, S.H., Kwon, E.K., Kim, E.M., Rha, M.Y., and Jin, D.K.: Increased density of ghrelin-expressing cells in the gastric fundus and body in Prader-Willi syndrome. J Clin Endocrinol Metab 90:5441-5445, 2005
40. Bagnasco, M., Tulipano, G., Melis, M.R., Argiolas, A., Cocchi, D., and Muller, E.E.: Endogenous ghrelin is an orexigenic peptide acting in the arcuate nucleus in response to fasting. Regul Pept 111:161-167, 2003
41. Tamura, H., Kamegai, J., Shimizu, T., Ishii, S., Sugihara, H., and Oikawa, S.: Ghrelin stimulates GH but not food intake in arcuate nucleus ablated rats. Endocrinology 143:3268-3275, 2002
42. Kamegai, J., Tamura, H., Shimizu, T., Ishii, S., Sugihara, H., and Wakabayashi, I.: Central effect of ghrelin, an endogenous growth hormone secretagogue, on hypothalamic peptide gene expression. Endocrinology 141:4797-4800, 2000
43.Nakazato, M., Murakami, N., Date, Y., Kojima, M., Matsuo, H., Kangawa, K., and Matsukura, S.: A role for ghrelin in the central regulation of feeding. Nature 409:194-198, 2001
44. Cowley, M.A., Smith, R.G., Diano, S., Tschop, M., Pronchuk, N., Grove, K.L., Strasburger, C.J., Bidlingmaier, M., Esterman, M., Heiman, M.L., Garcia-Segura, L.M., Nillni, E.A., Mendez, P., Low, M.J., Sotonyi, P., Friedman, J.M., Liu, H., Pinto, S., Colmers, W.F., Cone, R.D., and Horvath, T.L.: The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron 37:649-661, 2003
45. Hewson, A.K., and Dickson, S.L.: Systemic administration of ghrelin induces Fos and Egr-1 proteins in the hypothalamic arcuate nucleus of fasted and fed rats. J Neuroendocrinol 12:1047-1049, 2000
46. Kohno, D., Gao, H.Z., Muroya, S., Kikuyama, S., and Yada, T.: Ghrelin directly interacts with neuropeptide-Y-containing neurons in the rat arcuate nucleus: Ca2+ signaling via protein kinase A and N-type channel-dependent mechanisms and cross-talk with leptin and orexin. Diabetes 52:948-956, 2003
47. Lawrence, C.B., Snape, A.C., Baudoin, F.M., and Luckman, S.M.: Acute central ghrelin and GH secretagogues induce feeding and activate brain appetite centers. Endocrinology 143:155-162, 2002
48. Seoane, L.M., Lopez, M., Tovar, S., Casanueva, F.F., Senaris, R., and Dieguez, C.: Agouti-related peptide, neuropeptide Y, and somatostatin-producing neurons are targets for ghrelin actions in the rat hypothalamus. Endocrinology 144:544-551, 2003
49. Dickson, S.L., and Luckman, S.M.: Induction of c-fos messenger ribonucleic acid in neuropeptide Y and growth hormone (GH)-releasing factor neurons in the rat arcuate nucleus following systemic injection of the GH secretagogue, GH-releasing peptide-6. Endocrinology 138:771-777, 1997
50. Zigman, J.M., Jones, J.E., Lee, C.E., Saper, C.B., and Elmquist, J.K.: Expression of ghrelin receptor mRNA in the rat and the mouse brain. J Comp Neurol 494:528-548, 2006
51. Date, Y., Murakami, N., Toshinai, K., Matsukura, S., Niijima, A., Matsuo, H., Kangawa, K., and Nakazato, M.: The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. Gastroenterology 123:1120-1128, 2002
52. Faulconbridge, L.F., Cummings, D.E., Kaplan, J.M., and Grill, H.J.: Hyperphagic effects of brainstem ghrelin administration. Diabetes 52:2260-2265, 2003
53. Sun, Y., Ahmed, S., and Smith, R.G.: Deletion of ghrelin impairs neither growth nor appetite. Mol Cell Biol 23:7973-7981, 2003
54. Sun, Y., Wang, P., Zheng, H., and Smith, R.G.: Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor. Proc Natl Acad Sci U S A 101:4679-4684, 2004
55. Wortley, K.E., Anderson, K.D., Garcia, K., Murray, J.D., Malinova, L., Liu, R., Moncrieffe, M., Thabet, K., Cox, H.J., Yancopoulos, G.D., Wiegand, S.J., and Sleeman, M.W.: Genetic deletion of ghrelin does not decrease food intake but influences metabolic fuel preference. Proc Natl Acad Sci U S A 101:8227-8232, 2004
56. Zigman, J.M., Nakano, Y., Coppari, R., Balthasar, N., Marcus, J.N., Lee, C.E., Jones, J.E., Deysher, A.E., Waxman, A.R., White, R.D., Williams, T.D., Lachey, J.L., Seeley, R.J., Lowell, B.B., and Elmquist, J.K.: Mice lacking ghrelin receptors resist the development of diet-induced obesity. J Clin Invest 115:3564-3572, 2005
57. Wortley, K.E., del Rincon, J.P., Murray, J.D., Garcia, K., Iida, K., Thorner, M.O., and Sleeman, M.W.: Absence of ghrelin protects against early-onset obesity. J Clin Invest 115:3573-3578, 2005
58. Shuto, Y., Shibasaki, T., Otagiri, A., Kuriyama, H., Ohata, H., Tamura, H., Kamegai, J., Sugihara, H., Oikawa, S., and Wakabayashi, I.: Hypothalamic growth hormone secretagogue receptor regulates growth hormone secretion, feeding, and adiposity. J Clin Invest 109:1429-1436, 2002
59. Shearman, L.P., Wang, S.P., Helmling, S., Stribling, D.S., Mazur, P., Ge, L., Wang, L., Klussmann, S., Macintyre, D.E., Howard, A.D., and Strack, A.M.: Ghrelin neutralization by a ribonucleic acid-SPM ameliorates obesity in diet-induced obese mice. Endocrinology 147:1517-1526, 2006
60. Zorrilla, E.P., Iwasaki, S., Moss, J.A., Chang, J., Otsuji, J., Inoue, K., Meijler, M.M., and Janda, K.D.: Vaccination against weight gain. Proc Natl Acad Sci U S A 103:13226-13231, 2006
61. Govek, E.K., Longo, K.A., McDonagh, T., Ren, Y., Charonthongtrakul, S., Morgan, K., Zou, C., Saunders, J.O., Distefano, P.S., and Geddes, B.J.: Pharmacologic blockade of the ghrelin receptor (GhrR) recapitulates the phenotype of the GhrR knockout mouse: improved insulin sensitivity in high fat diet-fed mice by GhrR antagonist treatment. Diabetes 56 (Supp 1):A387, 2007
62. Esler, W.P., Rudolph, J., Claus, T.H., Tang, W., Barucci, N., Brown, S.E., Bullock, W., Daly, M., Decarr, L., Li, Y., Milardo, L., Molstad, D., Zhu, J., Gardell, S.J., Livingston, J.N., and Sweet, L.J.: Small-molecule ghrelin receptor
3. antagonists improve glucose tolerance, suppress appetite, and promote weight loss. Endocrinology, 2007
63. Zigman, J.M., and Elmquist, J.K.: Minireview: From anorexia to obesity--the yin and yang of body weight control. Endocrinology 144:3749-3756, 2003
64. Zigman, J.M., and Elmquist, J.K.: In search of an effective obesity treatment: a shot in the dark or a shot in the arm? Proc Natl Acad Sci U S A 103:12961-12962, 2006
65. Frezza, E.E., Wachtel, M.S., and Chiriva-Internati, M.: The multiple faces of glucagon-like peptide-1--obesity, appetite, and stress: what is next? A review. Dig Dis Sci 52:643-649, 2007
66. Merchenthaler, I., Lane, M., and Shughrue, P.: Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol 403:261-280, 1999
67. Fehse, F., Trautmann, M., Holst, J.J., Halseth, A.E., Nanayakkara, N., Nielsen, L.L., Fineman, M.S., Kim, D.D., and Nauck, M.A.: Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 90:5991-5997, 2005
68. Herman, G.A., Bergman, A., Liu, F., Stevens, C., Wang, A.Q., Zeng, W., Chen, L., Snyder, K., Hilliard, D., Tanen, M., Tanaka, W., Meehan, A.G., Lasseter, K., Dilzer, S., Blum, R., and Wagner, J.A.: Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J Clin Pharmacol 46:876-886, 2006
69. Aschner, P., Kipnes, M.S., Lunceford, J.K., Sanchez, M., Mickel, C., and Williams-Herman, D.E.: Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 29:2632-2637, 2006
70. Charbonnel, B., Karasik, A., Liu, J., Wu, M., and Meininger, G.: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 29:2638-2643, 2006
71. Meeran, K., O'Shea, D., Edwards, C.M., Turton, M.D., Heath, M.M., Gunn, I., Abusnana, S., Rossi, M., Small, C.J., Goldstone, A.P., Taylor, G.M., Sunter, D., Steere, J., Choi, S.J., Ghatei, M.A., and Bloom, S.R.: Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat. Endocrinology 140:244-250, 1999
72. Young, A.A., Gedulin, B.R., and Rink, T.J.: Dose-responses for the slowing of gastric emptying in a rodent model by glucagon-like peptide (7-36) NH2, amylin, cholecystokinin, and other possible regulators of nutrient uptake. Metabolism 45:1-3, 1996
73. Young, A.A., Gedulin, B.R., Bhavsar, S., Bodkin, N., Jodka, C., Hansen, B., and Denaro, M.: Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 48:1026-1034, 1999
74. Szayna, M., Doyle, M.E., Betkey, J.A., Holloway, H.W., Spencer, R.G., Greig, N.H., and Egan, J.M.: Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 141:1936-1941, 2000
75. Larsen, P.J., Fledelius, C., Knudsen, L.B., and Tang-Christensen, M.: Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes 50:2530-2539, 2001
76. Raun, K., von Voss, P., Gotfredsen, C.F., Golozoubova, V., Rolin, B., and Knudsen, L.B.: Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. Diabetes 56:8-15, 2007
77. Raun, K., von Voss, P., and Knudsen, L.B.: Liraglutide, a Once-daily Human Glucagon-like Peptide-1 Analog, Minimizes Food Intake in Severely Obese Minipigs. Obesity (Silver Spring) 15:1710-1716, 2007
78. Navarro, M., Rodriquez de Fonseca, F., Alvarez, E., Chowen, J.A., Zueco, J.A., Gomez, R., Eng, J., and Blazquez, E.: Colocalization of glucagon-like peptide-1 (GLP-1) receptors, glucose transporter GLUT-2, and glucokinase mRNAs in rat hypothalamic cells: evidence for a role of GLP-1 receptor agonists as an inhibitory signal for food and water intake. J Neurochem 67:1982-1991, 1996
79. Tang-Christensen, M., Vrang, N., and Larsen, P.J.: Glucagon-like peptide containing pathways in the regulation of feeding behaviour. Int J Obes Relat Metab Disord 25 Suppl 5:S42-47, 2001
80. Larsen, P.J., Tang-Christensen, M., and Jessop, D.S.: Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat. Endocrinology 138:4445-4455, 1997
81. Perez-Tilve, D., Gonzalez-Matias, L., Alvarez-Crespo, M., Leiras, R., Tovar, S., Dieguez, C., and Mallo, F.: Exendin-4 potently decreases ghrelin levels in fasting rats. Diabetes 56:143-151, 2007
82. DeFronzo, R.A., Ratner, R.E., Han, J., Kim, D.D., Fineman, M.S., and Baron, A.D.: Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28:1092-1100, 2005
83. Kendall, D.M., Riddle, M.C., Rosenstock, J., Zhuang, D., Kim, D.D., Fineman, M.S., and Baron, A.D.: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28:1083-1091, 2005
84. Blonde, L., Klein, E.J., Han, J., Zhang, B., Mac, S.M., Poon, T.H., Taylor, K.L., Trautmann, M.E., Kim, D.D., and Kendall, D.M.: Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 8:436-447, 2006
85. Ratner, R.E., Maggs, D., Nielsen, L.L., Stonehouse, A.H., Poon, T., Zhang, B., Bicsak, T.A., Brodows, R.G., and Kim, D.D.: Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab 8:419-428, 2006
86. Druce, M.R., and Bloom, S.R.: Oxyntomodulin : a novel potential treatment for obesity. Treat Endocrinol 5:265-272, 2006
87. Dakin, C.L., Small, C.J., Batterham, R.L., Neary, N.M., Cohen, M.A., Patterson, M., Ghatei, M.A., and Bloom, S.R.: Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 145:2687-2695, 2004
88. Dakin, C.L., Small, C.J., Park, A.J., Seth, A., Ghatei, M.A., and Bloom, S.R.: Repeated ICV administration of oxyntomodulin causes a greater reduction in body weight gain than in pair-fed rats. Am J Physiol Endocrinol Metab 283:E1173-1177, 2002
89. Cohen, M.A., Ellis, S.M., Le Roux, C.W., Batterham, R.L., Park, A., Patterson, M., Frost, G.S., Ghatei, M.A., and Bloom, S.R.: Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab 88:4696-4701, 2003
90. Wynne, K., Park, A.J., Small, C.J., Patterson, M., Ellis, S.M., Murphy, K.G., Wren, A.M., Frost, G.S., Meeran, K., Ghatei, M.A., and Bloom, S.R.: Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes 54:2390-2395, 2005
91. Roth, J.D., Hughes, H., Kendall, E., Baron, A.D., and Anderson, C.M.: Antiobesity effects of the beta-cell hormone amylin in diet-induced obese rats: effects on food intake, body weight, composition, energy expenditure, and gene expression. Endocrinology 147:5855-5864, 2006
92. Gedulin, B.R., Jodka, C.M., Herrmann, K., and Young, A.A.: Role of endogenous amylin in glucagon secretion and gastric emptying in rats demonstrated with the selective antagonist, AC187. Regul Pept 137:121-127, 2006
93. Young, A.: Inhibition of gastric emptying. Adv Pharmacol 52:99-121, 2005
94. Young, A.A., Gedulin, B., Vine, W., Percy, A., and Rink, T.J.: Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin. Diabetologia 38:642-648, 1995
95. Sexton, P.M., Paxinos, G., Kenney, M.A., Wookey, P.J., and Beaumont, K.: In vitro autoradiographic localization of amylin binding sites in rat brain. Neuroscience 62:553-567, 1994
96. Riediger, T., Schmid, H.A., Lutz, T.A., and Simon, E.: Amylin and glucose co-activate area postrema neurons of the rat. Neurosci Lett 328:121-124, 2002
97. Riediger, T., Zuend, D., Becskei, C., and Lutz, T.A.: The anorectic hormone amylin contributes to feeding-related changes of neuronal activity in key structures of the gut-brain axis. Am J Physiol Regul Integr Comp Physiol 286:R114-122, 2004
98. Lutz, T.A., Mollet, A., Rushing, P.A., Riediger, T., and Scharrer, E.: The anorectic effect of a chronic peripheral infusion of amylin is abolished in area postrema/nucleus of the solitary tract (AP/NTS) lesioned rats. Int J Obes Relat Metab Disord 25:1005-1011, 2001
99. Becskei, C., Grabler, V., Edwards, G.L., Riediger, T., and Lutz, T.A.: Lesion of the lateral parabrachial nucleus attenuates the anorectic effect of peripheral amylin and CCK. Brain Res, 2007
100. Lutz, T.A., Geary, N., Szabady, M.M., Del Prete, E., and Scharrer, E.: Amylin decreases meal size in rats. Physiol Behav 58:1197-1202, 1995
101. Morley, J.E., Flood, J.F., Horowitz, M., Morley, P.M., and Walter, M.J.: Modulation of food intake by peripherally administered amylin. Am J Physiol 267:R178-184, 1994
102. Smith, S.R., Blundell, J., Burns, C., Ellero, C., Schroeder, B.E., Kesty, N.C., Chen, K., Halseth, A.E., Lush, C.W., and Weyer, C.: Pramlintide Treatment Reduces 24-Hour Caloric Intake and Meal Sizes, and Improves Control of Eating in Obese Subjects: A 6-Week Translational Research Study. Am J Physiol Endocrinol Metab, 2007
103. Chapman, I., Parker, B., Doran, S., Feinle-Bisset, C., Wishart, J., Strobel, S., Wang, Y., Burns, C., Lush, C., Weyer, C., and Horowitz, M.: Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia 48:838-848, 2005
104. Hollander, P.A., Levy, P., Fineman, M.S., Maggs, D.G., Shen, L.Z., Strobel, S.A., Weyer, C., and Kolterman, O.G.: Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 26:784-790, 2003
105. Aronne, L., Fujioka, K., Aroda, V., Chen, K., Halseth, A., Kesty, N.C., Burns, C., Lush, C.W., and Weyer, C.: Progressive Reduction in Body Weight Following Treatment with the Amylin Analog Pramlintide in Obese Subjects: A Phase 2, Randomized, Placebo-Controlled, Dose-Escalation Study. J Clin Endocrinol Metab, 2007
106. Heisler, L.K., Cowley, M.A., Kishi, T., Tecott, L.H., Fan, W., Low, M.J., Smart, J.L., Rubinstein, M., Tatro, J.B., Zigman, J.M., Cone, R.D., and Elmquist, J.K.: Central serotonin and melanocortin pathways regulating energy homeostasis. Ann N Y Acad Sci 994:169-174, 2003
107. Heisler, L.K., Jobst, E.E., Sutton, G.M., Zhou, L., Borok, E., Thornton-Jones, Z., Liu, H.Y., Zigman, J.M., Balthasar, N., Kishi, T., Lee, C.E., Aschkenasi, C.J., Zhang, C.Y., Yu, J., Boss, O., Mountjoy, K.G., Clifton, P.G., Lowell, B.B., Friedman, J.M., Horvath, T., Butler, A.A., Elmquist, J.K., and Cowley, M.A.: Serotonin reciprocally regulates melanocortin neurons to modulate food intake. Neuron 51:239-249, 2006
108. Connolly, H.M., Crary, J.L., McGoon, M.D., Hensrud, D.D., Edwards, B.S., Edwards, W.D., and Schaff, H.V.: Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 337:581-588, 1997
109. Fitzgerald, L.W., Burn, T.C., Brown, B.S., Patterson, J.P., Corjay, M.H., Valentine, P.A., Sun, J.H., Link, J.R., Abbaszade, I., Hollis, J.M., Largent, B.L., Hartig, P.R., Hollis, G.F., Meunier, P.C., Robichaud, A.J., and Robertson, D.W.: Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 57:75-81, 2000
110. Heisler, L.K., Cowley, M.A., Tecott, L.H., Fan, W., Low, M.J., Smart, J.L., Rubinstein, M., Tatro, J.B., Marcus, J.N., Holstege, H., Lee, C.E., Cone, R.D., and Elmquist, J.K.: Activation of central melanocortin pathways by fenfluramine. Science 297:609-611, 2002
111. Heisler, L.K., and Tecott, L.H.: Knockout Corner: Neurobehavioural consequences of a serotonin 5-HT(2C) receptor gene mutation. Int J Neuropsychopharmacol 2:67-69, 1999
112. Tecott, L.H., Sun, L.M., Akana, S.F., Strack, A.M., Lowenstein, D.H., Dallman, M.F., and Julius, D.: Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature 374:542-546, 1995
113. Vickers, S.P., Clifton, P.G., Dourish, C.T., and Tecott, L.H.: Reduced satiating effect of d-fenfluramine in serotonin 5-HT(2C) receptor mutant mice. Psychopharmacology (Berl) 143:309-314, 1999
114. Arena Pharmaceuticals: Positive results from a Phase 2b clinical trial of Lorcaserin demonstrated highly statistically significant weight loss. http://www.arenapharm.com/wt/page/lho.html . 2006
115. Matsuda, L.A., Lolait, S.J., Brownstein, M.J., Young, A.C., and Bonner, T.I.: Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561-564, 1990
116. Matsuda, L.A., Bonner, T.I., and Lolait, S.J.: Localization of cannabinoid receptor mRNA in rat brain. J Comp Neurol 327:535-550, 1993
117. Lynn, A.B., and Herkenham, M.: Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. J Pharmacol Exp Ther 268:1612-1623, 1994
118. Foster-Schubert, K.E., and Cummings, D.E.: Emerging therapeutic strategies for obesity. Endocr Rev 27:779-793, 2006
119. Pagotto, U., Marsicano, G., Cota, D., Lutz, B., and Pasquali, R.: The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 27:73-100, 2006
120. Cota, D., Marsicano, G., Tschop, M., Grubler, Y., Flachskamm, C., Schubert, M., Auer, D., Yassouridis, A., Thone-Reineke, C., Ortmann, S., Tomassoni, F., Cervino, C., Nisoli, E., Linthorst, A.C., Pasquali, R., Lutz, B., Stalla, G.K., and Pagotto, U.: The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 112:423-431, 2003
121. Ravinet Trillou, C., Delgorge, C., Menet, C., Arnone, M., and Soubrie, P.: CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 28:640-648, 2004
122. Colombo, G., Agabio, R., Diaz, G., Lobina, C., Reali, R., and Gessa, G.L.: Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci 63:PL113-117, 1998
123. Di Marzo, V., Goparaju, S.K., Wang, L., Liu, J., Batkai, S., Jarai, Z., Fezza, F., Miura, G.I., Palmiter, R.D., Sugiura, T., and Kunos, G.: Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410:822-825, 2001
124. Jbilo, O., Ravinet-Trillou, C., Arnone, M., Buisson, I., Bribes, E., Peleraux, A., Penarier, G., Soubrie, P., Le Fur, G., Galiegue, S., and Casellas, P.: The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. Faseb J 19:1567-1569, 2005
125. Poirier, B., Bidouard, J.P., Cadrouvele, C., Marniquet, X., Staels, B., O'Connor, S.E., Janiak, P., and Herbert, J.M.: The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes Metab 7:65-72, 2005
126. Ravinet Trillou, C., Arnone, M., Delgorge, C., Gonalons, N., Keane, P., Maffrand, J.P., and Soubrie, P.: Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 284:R345-353, 2003
127. Liu, Y.L., Connoley, I.P., Wilson, C.A., and Stock, M.J.: Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int J Obes (Lond) 29:183-187, 2005
128. Van Gaal, L.F., Rissanen, A.M., Scheen, A.J., Ziegler, O., and Rossner, S.: Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365:1389-1397, 2005
129. Pi-Sunyer, F.X., Aronne, L.J., Heshmati, H.M., Devin, J., and Rosenstock, J.: Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. Jama 295:761-775, 2006
130. Despres, J.P., Golay, A., and Sjostrom, L.: Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353:2121-2134, 2005
131. Scheen, A.J., Finer, N., Hollander, P., Jensen, M.D., and Van Gaal, L.F.: Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 368:1660-1672, 2006
132. Curioni, C., and Andre, C.: Rimonabant for overweight or obesity. Cochrane Database Syst Rev:CD006162, 2006
133. Kakafika, A.I., Mikhailidis, D.P., Karagiannis, A., and Athyros, V.G.: The role of endocannabinoid system blockade in the treatment of the metabolic syndrome. J Clin Pharmacol 47:642-652, 2007
134. Sanofi-Aventis: FDA advisory committee did not recommend approval of rimonabant (zimluti) for use in obese and overweight patients with associated risks factors. http://www.sanofi-aventis.us/live/us/medias/20F41CB7-37FE-44F6-BF81-46EBF7BDB04A.pdf . 2007
135. Tuthill, A., Slawik, H., O'Rahilly, S., and Finer, N.: Psychiatric co-morbidities in patients attending specialist obesity services in the UK. Qjm 99:317-325, 2006
136. FDA. 2007. FDA Briefing Document NDA 21-888: Zimulti (rimonabant) Tablets, 20mg.
137. Sanofi-Aventis: Rimonabant regulatory update in the United States. http://www.sanofi-aventis.us/live/us/medias/07B70509-ED2F-4FCE-9533-EDB7187D57AB.pdf . 2007
138. Saper, C.B., Chou, T.C., and Elmquist, J.K.: The need to feed: homeostatic and hedonic control of eating. Neuron 36:199-211, 2002
139. Cummings, D.E., and Schwartz, M.W.: Genetics and pathophysiology of human obesity. Annu Rev Med 54:453-471, 2003
140. Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., and Friedman, J.M.: Positional cloning of the mouse obese gene and its human homologue. Nature 372:425-432, 1994
141. Farooqi, I.S., Jebb, S.A., Langmack, G., Lawrence, E., Cheetham, C.H., Prentice, A.M., Hughes, I.A., McCamish, M.A., and O'Rahilly, S.: Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 341:879-884, 1999
142. Hamilton, B.S., Paglia, D., Kwan, A.Y., and Deitel, M.: Increased obese mRNA expression in omental fat cells from massively obese humans. Nat Med 1:953-956, 1995
143. Lonnqvist, F., Arner, P., Nordfors, L., and Schalling, M.: Overexpression of the obese (ob) gene in adipose tissue of human obese subjects. Nat Med 1:950-953, 1995
144. Arch, J.R., Stock, M.J., and Trayhurn, P.: Leptin resistance in obese humans: does it exist and what does it mean? Int J Obes Relat Metab Disord 22:1159-1163, 1998
145. Heymsfield, S.B., Greenberg, A.S., Fujioka, K., Dixon, R.M., Kushner, R., Hunt, T., Lubina, J.A., Patane, J., Self, B., Hunt, P., and McCamish, M.: Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. Jama 282:1568-1575, 1999
146. Zelissen, P.M., Stenlof, K., Lean, M.E., Fogteloo, J., Keulen, E.T., Wilding, J., Finer, N., Rossner, S., Lawrence, E., Fletcher, C., and McCamish, M.: Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults: a randomized, placebo-controlled trial. Diabetes Obes Metab 7:755-761, 2005
147. Rosenbaum, M., Goldsmith, R., Bloomfield, D., Magnano, A., Weimer, L., Heymsfield, S., Gallagher, D., Mayer, L., Murphy, E., and Leibel, R.L.: Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. J Clin Invest 115:3579-3586, 2005
148. Fogteloo, A.J., Pijl, H., Frolich, M., McCamish, M., and Meinders, A.E.: Effects of recombinant human leptin treatment as an adjunct of moderate energy restriction on body weight, resting energy expenditure and energy intake in obese humans. Diabetes Nutr Metab 16:109-114, 2003
149. Boozer, C.N., Leibel, R.L., Love, R.J., Cha, M.C., and Aronne, L.J.: Synergy of sibutramine and low-dose leptin in treatment of diet-induced obesity in rats. Metabolism 50:889-893, 2001
150. Cowley, M.A., Pronchuk, N., Fan, W., Dinulescu, D.M., Colmers, W.F., and Cone, R.D.: Integration of NPY, AGRP, and melanocortin signals in the hypothalamic paraventricular nucleus: evidence of a cellular basis for the adipostat. Neuron 24:155-163, 1999
151. Barsh, G.S., Farooqi, I.S., and O'Rahilly, S.: Genetics of body-weight regulation. Nature 404:644-651, 2000
152. Huszar, D., Lynch, C.A., Fairchild-Huntress, V., Dunmore, J.H., Fang, Q., Berkemeier, L.R., Gu, W., Kesterson, R.A., Boston, B.A., Cone, R.D., Smith, F.J., Campfield, L.A., Burn, P., and Lee, F.: Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 88:131-141, 1997
153. Butler, A.A., Marks, D.L., Fan, W., Kuhn, C.M., Bartolome, M., and Cone, R.D.: Melanocortin-4 receptor is required for acute homeostatic responses to increased dietary fat. Nat Neurosci 4:605-611, 2001
154. Ollmann, M.M., Wilson, B.D., Yang, Y.K., Kerns, J.A., Chen, Y., Gantz, I., and Barsh, G.S.: Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science 278:135-138, 1997
155. Fan, W., Boston, B.A., Kesterson, R.A., Hruby, V.J., and Cone, R.D.: Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature 385:165-168, 1997
156. Giraudo, S.Q., Billington, C.J., and Levine, A.S.: Feeding effects of hypothalamic injection of melanocortin 4 receptor ligands. Brain Res 809:302-306, 1998
157. Xiang, Z., Pogozheva, I.D., Sorenson, N.B., Wilczynski, A.M., Holder, J.R., Litherland, S.A., Millard, W.J., Mosberg, H.I., and Haskell-Luevano, C.: Peptide and small molecules rescue the functional activity and agonist potency of dysfunctional human melanocortin-4 receptor polymorphisms(,). Biochemistry 46:8273-8287, 2007
158. Madison, L.D., and Marks, D.L.: Anticatabolic properties of melanocortin-4 receptor antagonists. Curr Opin Clin Nutr Metab Care 9:196-200, 2006
159. Cai, M., Mayorov, A.V., Ying, J., Stankova, M., Trivedi, D., Cabello, C., and Hruby, V.J.: Design of novel melanotropin agonists and antagonists with high potency and selectivity for human melanocortin receptors. Peptides 26:1481-1485, 2005
160. King, S.H., Mayorov, A.V., Balse-Srinivasan, P., Hruby, V.J., Vanderah, T.W., and Wessells, H.: Melanocortin receptors, melanotropic peptides and penile erection. Curr Top Med Chem 7:1111-1119, 2007
161. Palatin: Palatin Technologies. 2007
162. Renaud, S., and de Lorgeril, M.: Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 339:1523-1526, 1992
163. Guarente, L., and Picard, F.: Calorie restriction--the SIR2 connection. Cell 120:473-482, 2005
164. Picard, F., Kurtev, M., Chung, N., Topark-Ngarm, A., Senawong, T., Machado De Oliveira, R., Leid, M., McBurney, M.W., and Guarente, L.: Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 429:771-776, 2004
165. Chen, J., Zhou, Y., Mueller-Steiner, S., Chen, L.F., Kwon, H., Yi, S., Mucke, L., and Gan, L.: SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. J Biol Chem 280:40364-40374, 2005
166. Frescas, D., Valenti, L., and Accili, D.: Nuclear trapping of the forkhead transcription factor FoxO1 via Sirt-dependent deacetylation promotes expression of glucogenetic genes. J Biol Chem 280:20589-20595, 2005
167. Kolthur-Seetharam, U., Dantzer, F., McBurney, M.W., de Murcia, G., and Sassone-Corsi, P.: Control of AIF-mediated cell death by the functional interplay of SIRT1 and PARP-1 in response to DNA damage. Cell Cycle 5:873-877, 2006
168. Raval, A.P., Dave, K.R., and Perez-Pinzon, M.A.: Resveratrol mimics ischemic preconditioning in the brain. J Cereb Blood Flow Metab 26:1141-1147, 2006
169. Qiao, L., and Shao, J.: SIRT1 regulates adiponectin gene expression through Foxo1-C/enhancer-binding protein alpha transcriptional complex. J Biol Chem 281:39915-39924, 2006
170. Nemoto, S., Fergusson, M.M., and Finkel, T.: SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1{alpha}. J Biol Chem 280:16456-16460, 2005
171. Rodgers, J.T., Lerin, C., Haas, W., Gygi, S.P., Spiegelman, B.M., and Puigserver, P.: Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 434:113-118, 2005
172. Howitz, K.T., Bitterman, K.J., Cohen, H.Y., Lamming, D.W., Lavu, S., Wood, J.G., Zipkin, R.E., Chung, P., Kisielewski, A., Zhang, L.L., Scherer, B., and Sinclair, D.A.: Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425:191-196, 2003
173. Baur, J.A., Pearson, K.J., Price, N.L., Jamieson, H.A., Lerin, C., Kalra, A., Prabhu, V.V., Allard, J.S., Lopez-Lluch, G., Lewis, K., Pistell, P.J., Poosala, S., Becker, K.G., Boss, O., Gwinn, D., Wang, M., Ramaswamy, S., Fishbein, K.W., Spencer, R.G., Lakatta, E.G., Le Couteur, D., Shaw, R.J., Navas, P., Puigserver, P., Ingram, D.K., de Cabo, R., and Sinclair, D.A.: Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444:337-342, 2006
174. Lagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F., Messadeq, N., Milne, J., Lambert, P., Elliott, P., Geny, B., Laakso, M., Puigserver, P., and Auwerx, J.: Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127:1109-1122, 2006
175. Sirtris Pharmaceuticals: Sirtris Pharmaceuticals Presents Results of Studies of SIRT1 Activators at 6th Annual Metabolic Diseases Drug Discovery and Development World Summit, July 17, 2007. http://phx.corporate-ir.net/phoenix.zhtml?c=185399&p=irol-newsArticle&ID=1026899&highlight . 2007
176. National Library of Medicine: http://clinicaltrials.gov . 2007